In a major development for patients living with hereditary angioedema (HAE), the U.S. Food and Drug Administration (FDA) has approved Garadacimab‑gxii…..
The U.S. Food and Drug Administration (FDA) has approved IBTROZI (Taletrectinib) for the treatment of adult patients with locally advanced or metastatic……